UY25950A1 - Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea - Google Patents

Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea

Info

Publication number
UY25950A1
UY25950A1 UY25950A UY25950A UY25950A1 UY 25950 A1 UY25950 A1 UY 25950A1 UY 25950 A UY25950 A UY 25950A UY 25950 A UY25950 A UY 25950A UY 25950 A1 UY25950 A1 UY 25950A1
Authority
UY
Uruguay
Prior art keywords
same
treatment
prevention
resorption
oral
Prior art date
Application number
UY25950A
Other languages
English (en)
Spanish (es)
Inventor
Anastasia G Daifotis
Arthur C Santora Ii
A John Yates
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25950(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of UY25950A1 publication Critical patent/UY25950A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
UY25950A 1997-07-22 2000-01-17 Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea UY25950A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Publications (1)

Publication Number Publication Date
UY25950A1 true UY25950A1 (es) 2000-09-29

Family

ID=27451690

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25950A UY25950A1 (es) 1997-07-22 2000-01-17 Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea

Country Status (31)

Country Link
EP (5) EP1175903A3 (https=)
JP (2) JP3479780B2 (https=)
KR (3) KR100391732B1 (https=)
CN (3) CN1166365C (https=)
AT (2) ATE209037T1 (https=)
AU (1) AU8493698A (https=)
BG (1) BG66282B1 (https=)
BR (1) BR9810779A (https=)
CA (1) CA2294595C (https=)
CY (2) CY1107535T1 (https=)
DE (6) DE01201911T1 (https=)
DK (2) DK1175904T3 (https=)
EA (1) EA004544B2 (https=)
EE (1) EE05603B1 (https=)
ES (3) ES2164447T3 (https=)
HK (4) HK1042230A1 (https=)
ID (1) ID24096A (https=)
IL (1) IL133535A0 (https=)
IS (3) IS5315A (https=)
LU (2) LU91222I2 (https=)
NL (2) NL300223I1 (https=)
NO (1) NO20000323L (https=)
NZ (1) NZ501807A (https=)
PL (1) PL195272B1 (https=)
PT (2) PT1175904E (https=)
SG (2) SG139556A1 (https=)
SI (1) SI0998292T1 (https=)
SK (1) SK932000A3 (https=)
TR (1) TR200000145T2 (https=)
UY (1) UY25950A1 (https=)
WO (1) WO1999004773A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038694A1 (en) 1998-12-25 2000-07-06 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions for treating osseous lesion in multiple myeloma
PL351674A1 (en) * 1999-05-21 2003-05-19 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
EP1114642B1 (en) * 1999-07-19 2010-01-06 Toray Industries, Inc. Drugs for periodontal diseases
AU2270101A (en) * 1999-12-20 2001-07-03 Merck & Co., Inc. Pharmaceutical kit
AU2580001A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Blister package for pharmaceutical treatment card
AU2001251432A1 (en) * 2000-04-07 2001-10-23 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use ofthe compositions as bisphosphate delivery systems with reduced gi toxicity
ES2394211T3 (es) 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
SI1296689T1 (sl) * 2000-06-20 2006-08-31 Novartis Ag Nacin dajanja pacientu bisfosfonatov
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
KR20060058151A (ko) * 2002-05-10 2006-05-29 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
CA2539359A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
JPWO2005072747A1 (ja) * 2004-02-02 2007-09-13 小野薬品工業株式会社 骨吸収抑制剤
WO2007031785A2 (en) * 2005-09-16 2007-03-22 Selamine Ltd Bisphosphonate formulation
CA2820019A1 (en) * 2010-12-06 2012-06-14 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
ATE122228T1 (de) * 1991-07-01 1995-05-15 Gergely Gerhard Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung.
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
DK0648120T3 (da) * 1992-06-30 1998-01-19 Procter & Gamble Pharma Anvendelse af phosphonater til behandling af osteoporose
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
AU703887B2 (en) * 1995-06-06 1999-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
WO1997044017A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Effervescent bisphosphonate formulation

Also Published As

Publication number Publication date
WO1999004773A9 (en) 1999-10-28
HK1042232A1 (en) 2002-08-09
DE122007000063I1 (de) 2007-12-20
HK1024166A1 (en) 2000-10-05
ID24096A (id) 2000-07-06
PL338635A1 (en) 2000-11-06
EP1175904B8 (en) 2007-05-09
ES2253136T1 (es) 2006-06-01
IS7231A (is) 2004-04-21
DE69803291T2 (de) 2002-08-08
ATE209037T1 (de) 2001-12-15
DE69837450D1 (de) 2007-05-10
PL195272B1 (pl) 2007-08-31
EP0998292A2 (en) 2000-05-10
DE01201913T1 (de) 2007-02-08
BR9810779A (pt) 2000-07-25
CY1107535T1 (el) 2012-01-25
WO1999004773A2 (en) 1999-02-04
IS5315A (is) 1999-12-21
EA004544B1 (ru) 2004-06-24
EA004544B2 (ru) 2006-12-29
LU91364I2 (fr) 2007-11-12
CY2007022I1 (el) 2012-01-25
NL300292I1 (nl) 2007-11-01
PT1175904E (pt) 2007-04-30
DE69837450T2 (de) 2007-08-23
KR20030097611A (ko) 2003-12-31
EA200000151A1 (ru) 2000-10-30
NO20000323L (no) 2000-03-20
IL133535A0 (en) 2001-04-30
HK1042230A1 (en) 2002-08-09
ES2164447T3 (es) 2002-02-16
EP1175904A2 (en) 2002-01-30
HK1040494A1 (en) 2002-06-14
BG104093A (en) 2000-10-31
CN1299689C (zh) 2007-02-14
HK1040495A1 (en) 2002-06-14
LU91222I2 (fr) 2006-04-18
JP2005068010A (ja) 2005-03-17
ATE357921T1 (de) 2007-04-15
DK1175904T3 (da) 2007-05-07
IS7230A (is) 2004-04-21
CY2007022I2 (el) 2012-01-25
EE05603B1 (et) 2012-12-17
EP1175904B1 (en) 2007-03-28
PT998292E (pt) 2002-04-29
NL300223I1 (nl) 2006-04-03
DE122006000009I1 (de) 2006-06-14
EP1175903A2 (en) 2002-01-30
DE69803291D1 (de) 2002-02-21
KR20010022110A (ko) 2001-03-15
CA2294595A1 (en) 1999-02-04
DE01201911T1 (de) 2007-10-18
EP1132088A3 (en) 2002-04-24
KR100391732B1 (ko) 2003-07-16
SG109478A1 (en) 2005-03-30
JP2002502433A (ja) 2002-01-22
SK932000A3 (en) 2000-09-12
CN1602879A (zh) 2005-04-06
BG66282B1 (bg) 2013-01-31
EE200000040A (et) 2000-10-16
JP3479780B2 (ja) 2003-12-15
DK0998292T3 (da) 2002-05-13
TR200000145T2 (tr) 2000-05-22
CA2294595C (en) 2001-08-21
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
NZ501807A (en) 2003-02-28
EP1151752A2 (en) 2001-11-07
WO1999004773A3 (en) 1999-04-15
EP1151752A3 (en) 2002-12-18
CN1602880A (zh) 2005-04-06
EP1132088A2 (en) 2001-09-12
ES2269014T1 (es) 2007-04-01
AU8493698A (en) 1999-02-16
CN1265035A (zh) 2000-08-30
KR20030097610A (ko) 2003-12-31
ES2269014T3 (es) 2007-05-01
EP1175903A3 (en) 2002-12-18
SI0998292T1 (en) 2002-04-30
EP1175904A3 (en) 2002-12-18
CN1166365C (zh) 2004-09-15
EP0998292B1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
UY25950A1 (es) Procedimiento para preparar composiciones de tratamiento oral para la prevencion de la resorcion osea
US5853759A (en) Effervescent alendronate formulation
CA2254060C (en) Effervescent bisphosphonate formulation
ES2394211T3 (es) Procedimiento de administración de bifosfonatos
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
YU31795A (sh) Oralne tečne formulacije alendronata
JPH08505142A (ja) 骨損失を治療及び予防するためのビスホスホネート／エストロゲン療法
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
RU2006126783A (ru) Фармацевтические составы бисфосфонатов
DK0833643T3 (da) Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
MX9303243A (es) Compuestos de fosfonato novedosos que contienen nitrogeno cuaternario, composiciones farmaceuticas y metodos para tratar el metabolismo anormal del calcio y el fosfato, y metodos para tratar y prevenir calculos dentales y placa dental.
ES2060708T3 (es) Sistema terapeutico de liberacion retardada para formulaciones farmaceuticas liquidas.
McClung Bisphosphonates
AR013994A1 (es) Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
US6399592B1 (en) Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
ES2262145T3 (es) Composicion anabolica para la masa osea que comprende olpadronato.
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
RU2004122433A (ru) Способ лечения костных нарушений
ES2139013T3 (es) Compuestos de fosfonato que contienen nitrogeno cuaternario para tratar el metabolismo anormal del calcio y fosfato.
US20060034921A1 (en) Effervescent bisphosphonate formulation
US20040137058A1 (en) Effervescent bisphosphonate formulation
AR013500A1 (es) Uso de acido alendronico o una sal farmaceuticamente aceptable del mismo o una mezcal de los mismos para la manufactura de un medicamento
Moradi et al. Evaluation of Jaw Osteonecrosis Following Intra-Ligament Anesthesia in Zoledronate-Treated Rats: a Histological Evaluation

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20041115